AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01698476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)
Description: Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
Study NCT01698476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablets
Study NCT03314870 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Genetic signature
Description: To identify molecular signatures of EMT / immune status by using the random forest algorithm. The best signature will be measured by RT-qPCR and/or CATS-RNASeq technics.
Study NCT03026348 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV F Vaccine with Aluminum Phosphate Adjuvant
Study NCT03026348 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: RSV F Vaccine
Study NCT03584581 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Placebo
Study NCT04269083 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BIRC3
Description: BIRC3-expression directed preoperative chemoradiotherapy in patients with resectable adenocarcinoma of the esophagus and EGJ
Study NCT04269083 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BIRC3
Description: BIRC3-expression directed preoperative chemoradiotherapy in patients with resectable adenocarcinoma of the esophagus and EGJ
Study NCT00548548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.
Study NCT01122056 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise training
Description: Two 2-hours long interactive training to perform safe and efficient aerobic exercise for patients with multiple sclerosis
Study NCT03851172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Ophthalmic
Description: Preoperative administration of Ketorolac 0.5% eye drops
Study NCT00548548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.
Study NCT00548548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Capecitabine
Description: Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.
Study NCT00548548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.
Study NCT00548548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.
Study NCT03851172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nepafenac Ophthalmic
Description: Preoperative administration of Nepafenac 1 mg eye drops
Study NCT03851172 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclopentolate Ophthalmic
Description: Preoperative administration of Cyclopentolate eye drops
Study NCT03851172 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclopentolate Ophthalmic
Description: Preoperative administration of Cyclopentolate eye drops
Study NCT01836276 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: 1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
Study NCT01836276 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
Study NCT03452475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arterolane-piperaquine
Description: Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg)
Study NCT03452475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arterolane-piperaquine+mefloquine
Description: Arterolane maleate-piperaquine phosphate tablets (37.5 mg/187.5 mg) Mefloquine tablets (250 mg)
Study NCT03452475 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine
Description: Artemether-lumefantrine tablets (20 mg/120 mg)
Study NCT05266573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: The exercise program is led by an individual who has a background in exercise physiology and is trained by the Physical Therapist. The task oriented exercise program consists of 45 to 60 minutes of group exercise sessions with the following components: warm-up period (dual task activity and walking progressively), stretching/strengthening/balance (gradual progression of activities and repetitions for 30 minutes), and obstacle course (6 to 15 minutes of obstacle course and challenged walking).
Study NCT00331552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin hydrochloride
Description: Given IV
Study NCT00331552 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given orally
Study NCT00548548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo every 3 weeks, given until disease progression or unmanageable toxicity.
Study NCT00548548 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.
Study NCT00548548 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-fluorouracil
Description: For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.
Study NCT01356381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Dosage 50mg b.i.d.
Study NCT01356381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 50mg bid
Study NCT01823068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Patients will begin on once daily vandetanib at 300 mg with one cycle of 4 weeks.
Study NCT00000479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Participants will receive 100 mg of aspirin every other day.
Study NCT00000479 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin E
Description: Participants will receive 600 IU of vitamin E every other day.
Study NCT00331552 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00000479 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive placebo.
Study NCT02815722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SP2086
Description: The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
Study NCT02815722 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin
Description: The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
Study NCT00000479 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo.
Study NCT04122599 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melatonin
Description: Melatonin for prevent post stroke delirium
Study NCT03514082 — intervention group
Intervention type: DEVICE
Intervention: Rigid Thermoplastic Spinal Brace
Description: Custom made rigid thermoplastic brace with 23 hours daily wearing time.
Study NCT02970695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: magneto-auriculotherapy (MAT)
Description: Subjects will then receive MAT. The magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm.The experimental object will be applied to the seven selected acupoints as detected by an acupoint detector. Only one ear will receive treatment at a time, and the pellets will remain in situ for two days before the next change.
Study NCT02970695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: magneto-auriculotherapy (MAT)
Description: Subjects will then receive MAT. The magnetic pellets will have \~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm.The experimental object will be applied to the seven selected acupoints as detected by an acupoint detector. Only one ear will receive treatment at a time, and the pellets will remain in situ for two days before the next change.
Study NCT02970695 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Laser auriculotherapy (LAT)
Description: A laser device (Pointer Pulse™)15 will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm,2 and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. 16, 17 This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the selected acupoints. Laser protective goggles will be provided to the subjects and the researcher for eyes protection
Study NCT02970695 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser auriculotherapy (LAT)
Description: A laser device (Pointer Pulse™)15 will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm,2 and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. 16, 17 This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the selected acupoints. Laser protective goggles will be provided to the subjects and the researcher for eyes protection
Study NCT00511043 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PTK787
Description: PTK787 - 1250mg p.o. daily. Initial dose of 750mg p.o daily starting on day 1 and increased weekly to an intermediate dose of 1000 mg and then a target dose of 1250mg unless a grade ≥ 2 toxicity. Patients who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or patient non-compliance with the protocol requirement.
Study NCT03082001 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12% Sucrose
Study NCT03082001 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 24% Sucrose
Study NCT03604731 — intervention group
Intervention type: DEVICE
Intervention: cytokine adsorbtion during extracorporeal circulation
Description: preventive use of cytokine adsorption and modulation of the cytokine response in the course of artificial circulation
Study NCT01485614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sitagliptin
Description: Sitagliptin 100 mg tablet administered orally once daily
Study NCT01485614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Sitagliptin 100 mg tablet administered orally once daily
Study NCT01485614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg tablets administered orally starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily
Study NCT01485614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metformin
Description: Metformin 500 mg tablets administered orally starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily
Study NCT01485614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to sitagliptin
Description: Matching placebo to sitagliptin 100 mg tablet administered orally once daily
Study NCT01485614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to metformin
Description: Matching placebo to metformin 500 mg tablets, 2 tablets administered orally twice daily
Study NCT01485614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to metformin
Description: Matching placebo to metformin 500 mg tablets, 2 tablets administered orally twice daily
Study NCT01485614 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Glycemic Rescue 1
Description: Participants in the sitagliptin arm who require glycemic rescue will receive metformin during Weeks 0-20 and Weeks 20-54. Participants in the placebo arm who require glycemic rescue will receive metformin during Weeks 0-20. Participants in the placebo arm who have switched to metformin during Weeks 20-54 and require glycemic rescue will receive sitagliptin.
Study NCT01485614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glycemic Rescue 1
Description: Participants in the sitagliptin arm who require glycemic rescue will receive metformin during Weeks 0-20 and Weeks 20-54. Participants in the placebo arm who require glycemic rescue will receive metformin during Weeks 0-20. Participants in the placebo arm who have switched to metformin during Weeks 20-54 and require glycemic rescue will receive sitagliptin.
Study NCT01485614 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Glycemic Rescue 2
Description: Participants who require glycemic rescue after Glycemic Rescue 1 will receive open-label insulin. Participants on background insulin therapy will have the dose of their background insulin up-titrated.
Study NCT01485614 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Glycemic Rescue 2
Description: Participants who require glycemic rescue after Glycemic Rescue 1 will receive open-label insulin. Participants on background insulin therapy will have the dose of their background insulin up-titrated.
Study NCT02908399 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLIR ONE
Study NCT03695029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir Alafenamide
Description: Pregnant women receiving tenofovir alafenamide 25 mg per day since 26-32 weeks of pregnancy to 2-4 weeks postpartum.
Study NCT03168516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)
Description: Application of FiO2-C (provided by standard infant ventilators) in addition to manual adjustments of the inspired oxygen fraction (FiO2) during mechanical ventilation and continuous positive airway pressure (CPAP) in ELGANs at least up to 32weeks PMA according to a standardized protocol
Study NCT01786317 — intervention group
Intervention type: DEVICE
Intervention: High resolution manometry
Description: Anorectal High resoltion manometry using electronic sensors
Study NCT00191854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: 2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles
Study NCT00191854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 150 mg/m2, IV, every 14 days x 8 cycles
Study NCT00191854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles
Study NCT00191854 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 50 mg/m2, IV, every 14 days x 8 cycles
Study NCT01203644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SKY0402
Description: Single dose of SKY0402 administered locally into the surgical wound.
Study NCT01203644 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine HCl
Description: Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.
Study NCT03481179 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TMS
Description: Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause some discomfort with a mild headache sensation or nausea. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing spasticity inhibition. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
Study NCT03481179 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause some discomfort with a mild headache sensation or nausea. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing spasticity inhibition. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
Study NCT03481179 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Physical therapy
Description: The physical therapy, with an duration of 40-50 minutes, will be focused on the upper limbs and will be based on the principles of neuroplasticity (repetition, intensity, specificity, among others (KLEIM \& JONES, 2008), with a protocol that will cover different exercises and degrees of difficulty, which will be chosen according to the need and capacity of each patient
Study NCT03481179 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: The physical therapy, with an duration of 40-50 minutes, will be focused on the upper limbs and will be based on the principles of neuroplasticity (repetition, intensity, specificity, among others (KLEIM \& JONES, 2008), with a protocol that will cover different exercises and degrees of difficulty, which will be chosen according to the need and capacity of each patient
Study NCT04039100 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Family Caregiver Ambassador Support
Description: Family Caregiver Ambassador Support, with former caregivers of patients treated for hematological malignancies, being ambassadors for caregivers of newly diagnosed patients for a period of 12 weeks
Study NCT01239719 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone + clemastine
Description: Dexamethasone 0.5 mg clemastine fumarate: 01 tablet every 12 hours.
Study NCT01239719 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone 0.5 mg: 01 tablet every 12 hours.
Study NCT04321161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bicanorm
Description: Treatment of patients with relapsed AML after allo-HCT receiving DLIs with Bicanorm (1-1-1) for 7 days.~sodium hydrogen carbonate (1 g per 1 tablet) = sodium ion (11,9 mmol per 1 tablet) = sodium ion (273 mg per 1 tablet) = hydrogen carbonate ion (11,9 mmol per 1 tablet)
Study NCT03646084 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep and Circadian Intervention Program (SCIP) plus rehabilitation program
Description: To study circadian rhythm disorders and sleep disorders and develops the SCIP to improve sleep in the patients.
Study NCT03646084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation program
Description: Rehabilitation program current clinical practice
Study NCT04041115 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Non-alcoholic beer
Description: Treatment consisted of 330ml non-alcoholic beer per day, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.
Study NCT04041115 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: Treatment consisted of 330ml of water, plus an individualized dietary program and an exercise program with a pedometer-based bracelet to reach at least 5000 steps/day during 2 + 8 weeks.
Study NCT00955773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1120212 plus everolimus
Description: Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.
Study NCT03348436 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: radiofrequency ablation